SEC EDGARNov 10$HTFL

Farquhar John C.M. sold $2.2M of HTFL

Farquhar John C.M. (Chief Executive Officer) sold 38,900 shares of Heartflow, Inc. (HTFL) at $55.74 ($2.17M total) on 2026-11-10 under a Rule 10b5-1 trading plan.

Original reporting

SEC EDGAR · Farquhar John C.M.

Published Nov 10, 2026, 11:59 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Nov 11, 2026, 12:02 AM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefInsider activity

Primary signal

$HTFL

Bearish

medium confidence

Mentioned

$HTFL

Relevance

5/10

AlphAI data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$HTFLBearishLow

Why it matters

The disclosed sale adds supply pressure and may prompt short‑term price adjustments.

Market read

Insider sales are watched by traders for potential signals; this modest sale is unlikely to move the stock dramatically but may influence short‑term sentiment.

What to watch

Potential tax planning or portfolio rebalancing motives behind the 10b5‑1 execution.

Relevance 5/10Novelty 5/10Timing: same‑day filing

Background

Form 4 filings disclose insider transactions and are primary sources for such events.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$HTFLBearishMedium confidence

Context

CEO Farquhar sold 38,900 shares for $2.17M via a 10b5‑1 plan, reducing his stake to 251,983 shares.

Expected impact

likely downward pressure as the market absorbs the disclosed sale

Evidence & confidence

A $2.2M open‑market sale by the CEO signals potential confidence concerns and adds supply to the market.

Market effects

Sector

Minimal impact on the broader digital health sector.

Regional

Limited to U.S. investors tracking Heartflow.

Global

Low global relevance.

Counterpoint

What could challenge this read

The sale could be routine under a pre‑arranged plan and not reflect negative sentiment.

Key entities

Company
Heartflow, Inc.
Digital health company listed on NASDAQ under HTFL.
Person
Farquhar John C.M.
Chief Executive Officer of Heartflow.

Read at source ← All news

Med

HeartFlow: 3 Key Takeaways for Long-Term Investors

HeartFlow reported revenue growth outpacing expenses, narrowing operating losses. The company has $253M in cash and expects to achieve positive cash flow by mid-2028. It aims for an 85% non-GAAP gross margin and is expanding its platform with new products like PCI Navigator. Management highlights structural advantages and growing clinical evidence.

finance.yahoo.comNov 14

Med

Canaccord Genuity maintains HeartFlow at Buy, raises price target to $69 from $56

Canaccord Genuity raised its price target for HeartFlow to $69 from $56, maintaining a Buy rating. The new target suggests a 15.2% upside from the Nov 12 close of $59.92. Recent analyst price targets for HeartFlow range from $64 to $70.

tradingview.comNov 13

High

Stifel maintains HeartFlow at Buy, raises price target to $70 from $45

Stifel upgraded its price target for HeartFlow to $70 from $45, a 55.6% increase, implying 16.8% upside from the Nov 12 close of $59.92. The firm maintained its Buy rating on the company.

tradingview.comNov 13

$HTFLMed

Stifel raises HeartFlow stock price target to $70 on strong growth

Stifel raised its price target on HeartFlow (NASDAQ:HTFL) to $70 from $45, citing strong Q3 2026 results. Revenue was $72.9M, beating estimates and showing 57% YoY growth. The company raised its full-year revenue guidance to $262M-$264M. Shares are near a 52-week high, up 106% YTD, but some analysts consider the stock overvalued.

investing.comNov 13

$HTFLHighAI 8/10

HeartFlow (HTFL) Q3 2026 Earnings Call Transcript

HeartFlow (HTFL) reported Q3 2026 revenue of $72.9M, up 57% YoY, driven by Plaque adoption and FFRCT utilization. They raised full-year revenue guidance to $262M-$264M, up 49%-50% YoY. Non-GAAP gross margin guidance was increased to 82.5%, with midterm profitability goals reaffirmed. Commercial adoption and clinical evidence support growth.

finance.yahoo.comNov 13

$HTFLMedAI 8/10

What Heartflow (HTFL) Said on Its Q3 Earnings Call

Heartflow (HTFL) expects to reach cash flow profitability by mid-2028, with declining operating expenses and narrowing losses. The company anticipates 1,300 Plaque Analysis-activated accounts by year-end and 37% year-over-year FFRct volume growth in Q4. Plaque Analysis pricing is expected to be flat sequentially, with a 10% increase in Q1 2027. Clinical data shows Plaque Analysis reduces major cardiovascular events and heart attack rates.